Solid Tumor Gene Mutation Panel, NGS (Oncotype MAP™, Guardant360® CDx, Guardant Reveal™, PGDx elio™, Northstar Select®, oncoReveal™, LiquidHALLMARK®, PredicineATLAS™, GENESEEQPRIME™, Plasma Complete™)
The solid tumor mutation panel includes gene mutations, copy number variants and gene fusions associated with solid tumors. It uses next generation sequencing to identify the somatic variants in most commonly mutated genes in lung adenocarcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, melanoma, breast cancer, colon cancer, ovarian cancer, gastric cancer, thyroid carcinoma, head & neck cancer, skin cancer, liver cancer, bone cancer and prostate cancer. Solid tumors comprise approximately 95% of all malignancies and about 30% of all pediatric cancers. Although panels containing hundreds of genes have been developed the NCCN and other guidelines recommend small genetic panels targeted to a single type of tumor or the use of a single larger panel containing > 50 genes.
Panel Components
Although it depends on the laboratory and the clinical utility this panel uses DNA and RNA based, next-generation sequencing test that targets 50 genes to detect hotspot mutation (35 genes), copy number variants (19 genes), and gene fusions (21 genes). The panel includes following 50 genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VHL.
- As an aid in diagnosis of solid tumors related to most common solid organ neoplasm
- To assess for targeted variants that are useful for prognosis and/or treatment of individuals with solid tumors
- Identifying solid tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
Positive: Mutation or pathogenic variant or fusion at least in one gene among the entire tested genes. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative for mutation or pathogenic variant or fusion in any gene tested
Formalin-fixed, paraffin-embedded tissue, Liquid biopsy, Extracted DNA.
Stability
- Ambient: Indefinitely
- Refrigerated: Indefinitely
- Frozen: Unacceptable
- Cancer Sci. 2019; 110: 6–15. [PMID: 30338623]
- J Surg Res. 2017;220: 125-132. [PMID: 29180174]
- Genome Med. 2016;8: 136. [PMID: 28007036]
- Int J Mol Sci. 2016;17: 1579. [PMID: 27657050]
- Cancer Treat Rev. 2015;41: 1-8. [PMID: 25467110]
- Ann Oncol. 2015; 26: 1291–1299. [PMID: 25605744]
- Nature. 2014;513: 202-9. [PMID: 25079317]
- Cell. 2013;155: 858-68. [PMID: 24209623]